Equaly
Equaly is dedicated to unlocking the therapeutic potential of the innate immune system to develop innovative treatments for cancer, infectious diseases, and autoimmune diseases. Their platform modulates immune responses based on antigen-specific cells, enabling the development of new immunotherapies and biologicals. They focus on creating accessible therapies that aim to cure diseases at their core, rather than just alleviating symptoms, through collaborations and cutting-edge technology.
Industries
Nr. of Employees
small (1-50)
Equaly
Patents
Modulation of antigen immunogenicity by addition of epitopes recognized by NKT cells
US-11236127-B2
View DetailsModulation of antigen immunogenicity by deleting epitopes recognized by NKT cells
US-11091512-B2
View DetailsModulation of antigen immunogenicity by deleting epitopes recognized by NKT cells
US-9732118-B2
View Details
Modulation of antigen immunogenicity by addition of epitopes recognized by NKT cells
US-11236127-B2
View DetailsModulation of antigen immunogenicity by deleting epitopes recognized by NKT cells
US-11091512-B2
View DetailsModulation of antigen immunogenicity by deleting epitopes recognized by NKT cells
US-9732118-B2
View DetailsProducts
NKT-targeting platform for peptide discovery and protein optimization
A technology platform that identifies NKT-activating motifs in proteins, enables design and testing of short peptide immunotherapeutics, and supports engineering of proteins and viral vectors to reduce immunogenicity.
NKT-targeting platform for peptide discovery and protein optimization
A technology platform that identifies NKT-activating motifs in proteins, enables design and testing of short peptide immunotherapeutics, and supports engineering of proteins and viral vectors to reduce immunogenicity.
Services
Provision of expert laboratory support to identify NKT-activating motifs, produce candidate peptides/proteins and perform in vitro NKT activation testing on human samples.
Collaborative development and licensing models including exclusivity, upfronts, milestones and royalties for co-development or out-licensing of platform-enabled therapeutics.
Co-development projects combining internal R&D resources with external partners to advance platform-derived candidates or to apply the platform to partner targets.
Provision of expert laboratory support to identify NKT-activating motifs, produce candidate peptides/proteins and perform in vitro NKT activation testing on human samples.
Collaborative development and licensing models including exclusivity, upfronts, milestones and royalties for co-development or out-licensing of platform-enabled therapeutics.
Co-development projects combining internal R&D resources with external partners to advance platform-derived candidates or to apply the platform to partner targets.
Expertise Areas
- Innate immunology and NKT cell biology
- Peptide immunotherapeutic discovery
- Protein engineering to mitigate immunogenicity
- Preclinical assay development using human immune cells
Key Technologies
- NKT-activating peptide design
- Protein motif prediction and ranking algorithms
- Synthetic peptide synthesis
- Recombinant protein production
News & Updates
Mr. François Boitquin joined as the new CEO in June 2023, bringing leadership and strategic vision.
Mr. Fabrice du Chastel joined as CBO in March 2022, to drive growth and expand opportunities.
Selected by Pharma Tech Outlook as one of the most innovative biotech companies in Europe for 2022.
Announced in November 2021, covering expertise in Science, Finance, and Biotech Development Strategy.
Completed in August 2021 to support projects in gene therapy, gene editing, and vaccination.
Received €2.8 million subsidy in September 2020 for therapies targeting Fabry and Pompe diseases.
Mr. François Boitquin joined as the new CEO in June 2023, bringing leadership and strategic vision.
Mr. Fabrice du Chastel joined as CBO in March 2022, to drive growth and expand opportunities.
Selected by Pharma Tech Outlook as one of the most innovative biotech companies in Europe for 2022.
Announced in November 2021, covering expertise in Science, Finance, and Biotech Development Strategy.
Completed in August 2021 to support projects in gene therapy, gene editing, and vaccination.
Received €2.8 million subsidy in September 2020 for therapies targeting Fabry and Pompe diseases.